Amcasertib

DB14866InvestigationalSmall molecule

Amcasertib is under investigation in clinical trial NCT02483247 (A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer).

Formula / weight: C₃₁H₃₃N₅O₂S · 539.7 g/mol (avg)
Code names: BBI-503

Resolves to

Compound

UNIIGLY8ABW25VCAS1129403-56-0ChEMBLCHEMBL3707349

Structure

InChIKeyQDWKGEFGLQMDAM-ULJHMMPZSA-NSMILESCCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=CC=C(C=C23)C2=CSC(=N2)C2=CC=CC=C2)=C1C

Targets

P16234PDGFRA

What you can answer from here — as of April 23, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

9Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Amcasertib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account